Navigation Links
R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
Date:1/24/2011

TOKYO, Jan. 24, 2011 /PRNewswire/ -- R-Tech Ueno, Ltd. is pleased to announce that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia (note 1) was completed by January 21, 2011.

Our company focuses on the area of no topical prescription drug in the market of androgenetic alopecia treatment and has developed a new topical drug. The Phase 2a clinical study of RK-023 for androgenetic alopecia treatment was performed in 48 patients with mild-to-moderate androgenetic alopecia, adult males aged 44 or less, to evaluate safety and pharmacokinetics, and efficacy.  RK-023 was applied repeatedly for 13 weeks.

This clinical study was a double-masked (Note 2), randomized and placebo-controlled (Note 3) study under Good Clinical Practice (GCP), and RK-023 was applied 2 mL each to a hair-thinning part of scalp twice daily in the patients with androgenetic alopecia. Laboratory tests, vital signs (blood pressure, pulse rate, body temperature and respiratory rate) and electrocardiogram were examined as the safety assessment.  Concentrations of RK-023 and its main metabolite in plasma were determined as a pharmacokinetic study. Dermatologic examination for the degree of baldness, global photo assessment, subject self-assessment and phototrichogram (Note 4) were examined as the efficacy assessment.

Forty-eight patients (24 cases of the RK-023 group and 24 cases of the placebo group) were enrolled in this study. There was no severe adverse event. The frequency of mild adverse events was equal in both groups. In pharmacokinetic study, the main metabolite of RK-023 was slightly detected in plasma of only one patient. This showed that the transdermal absorption of RK-023 from the scalp was low. In the efficacy assessment, the RK-023 group showed possibility of improvement in global photo assessment and in numbers of anagen hair (Note 4) from the baseline compared with the placebo group.

The president of R-Tech Ueno, Yukihiko Mash
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
3. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014   Memorial Hermann Health System ... Center today announced a new partnership to provide a ... community breast care centers in the greater Houston ... Anderson will become the exclusive provider of professional breast radiology ... located in Memorial City, The Woodlands , ...
(Date:8/21/2014)... 21, 2014 Nektar Therapeutics (NASDAQ: ... announced positive results from its Phase 3 pivotal ... half-life recombinant factor VIII (rFVIII) treatment for hemophilia ... met its primary endpoint in reducing annualized bleed ... the on-demand arm. Top-line results from ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... 6, 2011 NeuroSigma, Inc., a Los Angeles-based ... a notice of award for an NIH Small ... the National Institute of Neurological Disorders and Stroke ... trigeminal nerve stimulation (eTNS™) therapy for the treatment ...
... NEW YORK, Sept. 6, 2011 ... research report is available in its ... Vaccines - Cell Culture Technology Gradually ... http://www.reportlinker.com/p0610894/Manufacturing-of-Vaccines---Cell-Culture-Technology-Gradually-Replacing-Egg-Based-Manufacturing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Manufacturing ...
Cached Medicine Technology:NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy 2Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 2Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 3Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 4Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 5Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 6Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 7
(Date:8/22/2014)... CO (PRWEB) August 22, 2014 ... provider of in-home care for seniors, is proud to ... Webinar Series. The upcoming webinar will feature Dr. Suzanne ... at Lenox Hill Hospital in New York City, National ... and author. The webinar will cover the issues surrounding ...
(Date:8/22/2014)... News) -- College can be a challenging time for young ... do to make the most of their new life, an ... meet new people and learn to manage the temptations of ... assessment at St. John,s University in New York City, said ... place in the classroom. College is a time when students ...
(Date:8/22/2014)... 22, 2014 ItsHot.com, a client-centric manufacturer, ... 60-80% off on its range of beautiful diamond heart ... of Gold Hearts 14K White Rose Gold Diamond Heart ... discount of 77%. Previously priced at $3,715.00, customers can ... item code of this mesmerizing pendant embedded with 0.66 ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 According ... Type & Application - Global Trends & Forecast ... with an analysis and forecast of the market ... to $38,729 million by 2019, at a significant ... market data tables and 44 figures spread through ...
(Date:8/22/2014)... Each year approx. 265,000 Danes are acutely admitted to ... from Aarhus University and Aarhus University Hospital now shows ... fourth patient are sent home again without receiving ... the acute hospitalisation., "Naturally, there is no need for ... that there is a serious illness. So some patients ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:College Prep 101 2Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Many patients are discharged without a diagnosis 2
... By Maureen Salamon HealthDay Reporter , WEDNESDAY, ... risk of developing breast cancer by avoiding unnecessary medical ... but they don,t need to worry about using hair ... Reviewing the body of research on environmental factors ...
... HILL, N.C. -- New research from the University of ... may help explain the failure of some recent clinical trials ... others that used the same drugs. The study published ... Medicine , also suggests how to improve the chances for ...
... The behavior of consumers who are faced with making decisions ... health messages are worded or framed, according to a large, ... other institutions., The results of the study, published today (Dec. ... contradict the premise of the framing effect on making health ...
... There is still a one in eight lifetime risk that ... against the disease remains early detection. Now, Women & infants ... to the next level with the installation of the most ... & Infants is the first and only facility in southeastern ...
... , WEDNESDAY, Dec. 7 (HealthDay News) -- Two U.S. Food ... whether to recommend new warning labels about increased risk of ... The Reproductive Health Drugs Advisory Committee and the Drug Safety ... the public, and then make a recommendation to the full ...
... that affect the levels of an important brain protein involved ... seen during aging, according to an animal study in the ... The findings could one day aid in the development of ... Aging-related memory loss is associated with the gradual deterioration of ...
Cached Medicine News:Health News:Expert Panel Pinpoints Environmental Culprits in Breast Cancer 2Health News:Expert Panel Pinpoints Environmental Culprits in Breast Cancer 3Health News:Expert Panel Pinpoints Environmental Culprits in Breast Cancer 4Health News:When prophecy fails: How to better predict success in HIV prevention clinical trials 2Health News:When prophecy fails: How to better predict success in HIV prevention clinical trials 3Health News:Behavior of people faced with health-care choices is not influenced by 'framing effect,' study finds 2Health News:Behavior of people faced with health-care choices is not influenced by 'framing effect,' study finds 3Health News:Hospital gives first tomosynthesis mammograms in region this week 2Health News:FDA Panels to Weigh Safety of Newer Forms of the 'Pill' 2Health News:FDA Panels to Weigh Safety of Newer Forms of the 'Pill' 3Health News:Drug reverses aging-associated changes in brain cells 2